ArticleImmunoTargets and therapy2026
Macrophage-Derived Transcriptional Signatures Predict Prognosis and Drug Sensitivity in Thyroid Cancer: Integrative Analysis and Experimental Validation of SMYD3.
Article in ImmunoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid cancer is the most common malignancy of the endocrine system. Tumor-associated macrophages (TAMs) play a pivotal role in modulating the tumor microenvironment and promoting tumor progression. However, the prognostic implications of macrophage heterogeneity in thyroid cancer remain unclear. Methods: Single-cell RNA-seq analysis was conducted to identify tumor-enriched macrophage subpopulations and hdWGCNA was used to define related gene modules. A prognostic model was built using 117 machine learning algorithm combinations and validated by Kaplan-Meier analysis. A nomogram combining clinical features and risk scores was established. Genomic alterations, immune profiles, and treatment responses were compared between risk groups using TCGA and GDSC2 datasets. In vitro experiments were performed to validate the role of SMYD3 in tumor progression and drug sensitivity. Results: Single-cell analysis identified a tumor-enriched macrophage subset with distinct functional states. hdWGCNA revealed macrophage-related gene modules linked to poor prognosis, and a machine learning-based model effectively stratified patient risk. High-risk patients had worse survival, older age, advanced stage, and lower BRAF mutation frequency but more diverse oncogenic alterations. They also showed enhanced T-cell exclusion and altered immune infiltration. Drug prediction analysis indicated greater sensitivity to Rapamycin, BDP-00009066, AZD5363_1916, and Cediranib_1922 in the high-risk group. Functional assays confirmed that SMYD3 knockdown suppressed proliferation and migration, and reduced sensitivity to AZD5363_1916, highlighting its role in modulating therapeutic response. Conclusion: This study identifies a tumor-enriched macrophage subpopulation with prognostic relevance and develops a robust machine learning-based model for risk stratification in thyroid cancer. SMYD3 is implicated in both tumor progression and drug sensitivity, offering a potential biomarker for precision treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.